Journal of Thrombosis and Thrombolysis

, Volume 29, Issue 2, pp 199–207

Update on heparin: what do we need to know?

Article

DOI: 10.1007/s11239-009-0411-6

Cite this article as:
Weitz, D.S. & Weitz, J.I. J Thromb Thrombolysis (2010) 29: 199. doi:10.1007/s11239-009-0411-6

Abstract

Over the last 15 years, there has been a shift from unfractionated heparin to low-molecular-weight heparin or fondaparinux for many indications. Nonetheless, heparin continues to be used and it remains the drug of choice for selected indications and patients. This paper reviews when and how to use heparin and when low-molecular-weight heparin or fondaparinux may be a better choice. The paper also describes some of the new parenteral anticoagulants under development and provides perspective on how the introduction of rapid-acting oral thrombin or factor Xa inhibitors is likely to reduce or eliminate the need for bridging with parenteral anticoagulants.

Keywords

HeparinLow-molecular-weight heparinFondaparinuxParenteral anticoagulants

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  1. 1.Departments of Medicine & BiochemistryMcMaster University, and Henderson Research CentreHamiltonCanada
  2. 2.Henderson Research CentreHamiltonCanada